A study is conducted for a pharmaceutical agent that has shown promise for reducing heart disease among women. In order to more fully test the agent, an additional study is done restricting the participants to be randomized to those who have a history of hypertension. Which of the following advantages cannot be claimed by the researchers?
A) Power of the study is increased
B) Potential benefits in high-risk populations are increased
C) Validity of the study is increased by focus on a homogenous population
D) The generalizability of the study is increased
E) The overall cost of the study is decreased